Scientists discover why ozempic may not work for some people
New research from Stanford Medicine indicates that approximately 10% of people carry genetic variants that cause resistance to GLP-1 receptor agonists like Ozempic. This finding explains why some patients with Type 2 diabetes do not see effective blood sugar control with these medications.
Why it matters
Understanding genetic resistance to popular diabetes drugs is a critical step toward personalized medicine and improving treatment outcomes for patients.
More than one-quarter of people with Type 2 diabetes now use GLP-1 receptor agonists, a class of medications that includes Ozempic. But new research from Stanford Medicine and international collaborators suggests these widely prescribed drugs may be less effective for some patients because of their genetics.
The article is a straightforward summary of a peer-reviewed scientific study.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in